Akero Therapeutics Inc - ESG Rating & Company Profile powered by AI
Detailed Sustainability assessment of Akero Therapeutics Inc can be accessed by signing up for free. Other corporations in the rating peer group for Akero Therapeutics Inc are displayedin the table. This ESG score for Akero Therapeutics Inc indicates its transparency towards the United Nations Sustainable Development Goals.
Akero Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.5; made up of an environmental score of 4.0, social score of 1.6 and governance score of 4.8.
3.5
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1144 | Veerhealth Care Ltd | 3.6 | Medium |
| 1144 | iStreet Network Ltd | 3.6 | Medium |
| 1186 | Akero Therapeutics Inc | 3.5 | Medium |
| 1186 | CRISPR Therapeutics AG | 3.5 | Medium |
| 1186 | Catalent Inc | 3.5 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Akero Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Akero Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Akero Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Akero Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Akero Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Akero Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Akero Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Akero Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Akero Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Akero Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Akero Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Akero Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Akero Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Akero Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Akero Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Akero Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Akero Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Akero Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Akero Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Akero Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Akero Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Akero Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Akero Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Akero Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Akero Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Akero Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Akero Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Akero Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Akero Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Akero Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Akero Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Akero Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Akero Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Akero Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Akero Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Akero Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Akero Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.